

Patient Blood Management

Andrea Harris
NHSBT PBM Regional Lead


What is PBM?

‘Patient Blood Management’

- Views the patient’s own blood as a valuable and unique natural resource that should be conserved and managed appropriately
- An evidence-based, multidisciplinary team approach to optimising the care of patients who might need transfusion
- Focuses on measures for blood avoidance as well as correct use of blood components when they are needed
- Improves patient care – optimises use of donor blood and reduces transfusion-associated risks
- International initiative

For example, PBM in the USA

And Australia



Obstetrics } modules are in
Paediatrics / Neonate } development

Sixty-third World Health Assembly

Date: 17–21 May 2010

Location: Geneva, Switzerland

The Sixty-third session of the World Health Assembly took place in Geneva during 17–21 May 2010. At this session, the Health Assembly discussed a number of public health issues, including:

**WHA63.12 adopted
by resolution May 21, 2010:**



„Bearing in mind that **patient blood management means** that before surgery every reasonable measure should be taken to **optimize the patient’s own blood volume, to minimize the patient’s blood loss and to harness and optimize the patient-specific physiological tolerance of anaemia** following WHO’s guide for optimal clinical use (**three pillars of patient blood management**)“


Australia and Austria refer to '3 pillars':

Blood and Transplant

	1st Pillar Optimise erythropoiesis	2nd Pillar Minimise blood loss & bleeding	3rd Pillar Harness & optimise physiological reserve of anaemia
Preoperative	<ul style="list-style-type: none"> - Detect anaemia - Identify underlying disorder(s) causing anaemia - Manage disorder(s) - Refer for further evaluation if necessary - Treat suboptimal iron stores/iron deficiency/anemia of chronic disease/iron-restricted erythropoiesis - Treat other haematinic deficiencies - Note: Anaemia is a contraindication for elective surgery 	<ul style="list-style-type: none"> - Identify and manage bleeding risk - Minimising iatrogenic blood loss - Procedure planning and rehearsal - Preoperative autologous blood donation (in selected cases or when patient choice) - Other 	<ul style="list-style-type: none"> - Assess/optimize patient's physiological reserve and risk factors - Compare estimated blood loss with patient-specific tolerable blood loss - Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia - Restrictive transfusion thresholds
Intraoperative	<ul style="list-style-type: none"> - Timing surgery with haematological optimisation 	<ul style="list-style-type: none"> - Meticulous haemostasis and surgical techniques - Blood-sparing surgical techniques - Anaesthetic blood conserving strategies - Autologous blood options - Pharmacological/haemostatic agents 	<ul style="list-style-type: none"> - Optimise cardiac output - Optimise ventilation and oxygenation - Restrictive transfusion thresholds
Postoperative	<ul style="list-style-type: none"> - Stimulate erythropoiesis - Be aware of drug interactions that can increase anaemia 	<ul style="list-style-type: none"> - Vigilant monitoring and management of post-operative bleeding - Avoid secondary haemorrhage - Rapid warming / maintain normothermia (unless hypothermia specifically indicated) - Autologous blood salvage - Minimising iatrogenic blood loss - Haemostasis/anticoagulation management - Prophylaxis of upper GI haemorrhage - Avoid/treat infections promptly - Be aware of adverse effects of medication 	<ul style="list-style-type: none"> - Optimise anaemia reserve - Maximise oxygen delivery - Minimise oxygen consumption - Avoid/treat infections promptly - Restrictive transfusion thresholds


Detection and management of anaemia

Blood and Transplant



Patient Blood Management in England

CMO's Health Service Circulars 'Better Blood Transfusion'



PBM was 'launched' in England in 2012

- PBM conference June 2012
- Conference opened by Sir Bruce Keogh
- Presentations and workshops looking at how PBM can be implemented going forward
- Recommendations due to be launched very soon



Rationale for PBM


- Patient choice
- Blood supply issues
- Cost of blood
- Evidence of variable / inappropriate use
- Transfusion safety and effectiveness

Patient choice

Patient choice

Q: Would you share body fluids with a complete stranger?

A: Only to save my life!



Public perceptions of the risk of transfusion

Consent for Transfusion

SaBTO

Advisory Committee on the Safety of
Blood, Tissues and Organs



Recommendations
issued 2011

Prospective Information

Valid consent* should be obtained prior to any planned transfusion and documented in the patient's clinical record.

*Valid consent entails the provision of information on risks, benefits and alternatives available before asking the patient to give consent. This does not have to include a signature from the patient.

Retrospective Information

Patients treated in emergency setting where it was not possible to obtain valid consent pre-transfusion.

Patients who were told pre-procedure (e.g. pre-operatively) that they *might* require a transfusion then need to be informed whether they did/did not receive a transfusion.

Key issues to be discussed when obtaining valid consent

1. The following information should be discussed:
 - Type of blood / blood component
 - Indication for transfusion
 - Benefits of the transfusion
 - Risks of transfusion
 - Possible alternatives to transfusion
 - How the transfusion is administered and the importance of correct patient identification
 - Inform patient that following a blood transfusion they can no longer be a blood donor.
2. Provide written information.
3. Check if patient needs time to consider or requires further information.
4. Document the discussion in the patient's clinical records.

At discharge

1. If patient has had a transfusion, ensure that they have been informed.
2. Record information about the transfusion in the discharge summary, also stating that the patient has been informed.


Blood supply issues

Blood demand and supply




Blood and Transplant


Red cells



Platelets




Active donor base



Red Blood Cell Stocks

(8th May 2014)



Urgent Communication

An electronic copy of this fax can be found on the Hospitals & Science 'Home Page' via the urgent area highlighted in red - <http://hospital.blood.co.uk/>

12th March 2014

All Transfusion Laboratory Managers in hospitals served by NHS Blood and Transplant

Dear Colleague

Stocks of B RhD Negative and O RhD Negative Red Cells

NHSBT continually monitors stocks with the aim to maintain levels of all blood groups above 3 days. Due to an increase in demand, stocks of group B RhD negative and O RhD negative red cells have fallen, all other blood groups remain stable and it is not our intention to ask hospitals to activate their emergency blood management plan.

Action for Hospitals

In order to rebuild stocks, we have been encouraging more donors with these blood groups to donate and increased our processing activity. We will also need your support.

- O RhD negative red cells should only be used when necessary to prevent O RhD negative stock levels falling further. For B RhD negative we ask that hospitals use B RhD positive red cells as an alternative for suitable patients. In line with the established transfusion guidelines <http://www.transfusionguidelines.org.uk/index.aspx>

We apologise for any extra work that this will cause. Efforts will continue to bring about an improvement at the earliest opportunity and will ensure that you are kept advised of progress.

URGENT COMMUNICATION - PLATELET STOCKS

An electronic copy of this fax can be found on the Hospitals & Science "Home Page" via the urgent area highlighted in red - <http://hospital.blood.co.uk/>

Date: 23 April 2014

To: All Transfusion Laboratory Managers in hospitals served by NHSBT

Dear Colleagues

Platelet Stock Levels - Group A RhD negative

We are currently experiencing low stock levels of group A RhD negative platelets. We anticipate that these low levels will result in some shortage of supply and the need for substitutions. We do have good supplies of other groups available for appropriate substitution and will work with you to supply to your needs. We will not be able to offer group A RhD negative platelets for non emergency cover. i.e. platelets with a long shelf life held to avoid additional deliveries.

We are taking action to bring stocks back to normal through increased donor and manufacturing activity. However, this situation is expected to continue for a week or more whilst stocks rebuild to normal levels.

We will continue to monitor progress and we will keep you updated on stock levels and deliveries.







Hospital Action:

1. Please avoid making requests for long dated group A RhD negative platelets.
2. When ordering group A RhD negative for clinical use, where possible please specify a substitution that would best meet your patient needs. If you do not specify a substitution Hospital Services will offer an appropriate substitution.
3. If you require A RhD negative platelets for clinical use please indicate the date and time you require the platelets for transfusion. Please let our Hospital Services team know immediately if the urgency of any order changes.
4. When platelets have been ordered they may not arrive on your routine round and may be sent by free ad-hoc at a later time. Your platelet order may arrive from a different

Some blood supply challenges....



Blood and Transplant



Patient Blood Management

Cost of blood

Standard red cells	Platelets (ATD)
£121.85	£196.96

Evidence of variable / inappropriate use

Approx 60% of transfusions are for medical patients.

National Comparative Audit of Red Cell Use in Medicine (2011) indicated approx 13% are inappropriate!


(5% potentially reversible anaemia, 8% transfused above recommended thresholds)

NHSBT supplied approximately 1,700,000 adult units red cells 2013/14.

**~132,000 units
in medicine alone**

Transfusion safety and effectiveness

Figure 1: Cumulative data for SHOT categories 1996/7–2012 (n=11,570)



CABG Outcomes PBMP vs Non-PBMP

Outcome	PBMP cohort (n=586)	Non-PBMP cohort (n=586)	P-value
% Transfused	10.6%	42.5%	<0.0001
Mortality	0.8%	2.5%	0.02
Serious complication	11.1%	18.7%	0.0002

Moskowitz et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?
Ann Thorac Surg 2010;90:451-9

Allogeneic Blood Transfusion Increases the Risk of Postoperative Bacterial Infection: A Meta-analysis

Gary E. Hill, MD, William H. Frawley, PhD, Karl E. Griffith, MD, John E. Forestner, MD, and Joseph P. Minei, MD

Background: Immunosuppression is a consequence of allogeneic (homologous) blood transfusion (ABT) in humans and is associated with an increased risk in cancer recurrence rates after potentially curative surgery as well as an increase in the frequency of postoperative bacterial infections. Although a meta-analysis has been reported demonstrating the relationship between ABT and colon cancer recurrence, no meta-analysis has been reported demonstrating the relationship of ABT to postoperative bacterial infection.

Methods: Twenty peer-reviewed articles published from 1986 to 2000 were included in a meta-analysis. Criteria for inclusion included a clearly defined control group (nontransfused) compared with a treated (transfused) group and statistical analysis of accumulated data that included stepwise multivariate logistic regression analysis. In addition, a subgroup of publica-

tions that included only the traumatically injured patient was included in a separate meta-analysis. A fixed effects analysis was conducted with odds ratios obtained by using the conditional maximum likelihood method and 95% confidence intervals on the obtained odds ratios were determined using the mid-*p* technique.

Results: The total number of subjects included in this meta-analysis was 13,152 (5,215 in the transfused group and 7,937 in the nontransfused group). The common odds ratio for all articles included in this meta-analysis evaluating the association of ABT to the incidence of postoperative bacterial infection was 3.45 (range, 1.43–15.15), with 17 of the 20 studies demonstrating a value of $p \leq 0.05$. These results provide overwhelming evidence that ABT is associated with a significantly increased risk of postoperative bacterial infection in the surgical patient. The common odds ratio of the

subgroup of trauma patients was 5.263 (range, 5.03–5.43), with all studies showing a value of $p < 0.05$ (0.005–0.0001). These results demonstrate that ABT is associated with a greater risk of postoperative bacterial infection in the trauma patient when compared with those patients receiving ABT during or after elective surgery.

Conclusion: These results demonstrate that ABT is an associated and apparently significant and frequently overlooked risk factor for the development of postoperative bacterial infection in the surgical patient. Allogeneic blood transfusion is a greater risk factor in the traumatically injured patient when compared with the elective surgical patient for the development of postoperative bacterial infection.

Key Words: Meta-analysis, Blood transfusion, Immunosuppression, Postoperative infection, Trauma.

Why is PBM important worldwide?

Best practice: healthcare professionals want to ensure good outcomes for the patients/public they serve

Transfusion reduction potentially:

- shortens hospital length of stay
- reduces risk of infection, and or pulmonary complications
- reduces risk; product related infection, donor contamination, or human error of delivery of product

The Telegraph

“Killed by a needless blood transfusion”

Judy Kenny, whose husband was the first to die from vCJD contracted via a blood transfusion, is campaigning for tighter controls over the procedure

'To this day I don't know why Deryck needed that transfusion' – Judy Kenny at home in Bournemouth, with a picture of her late husband Deryck
15 Oct 2012



Question:

So is PBM all about reducing blood usage?

Answer:

No - not exactly....

‘Patient Blood Management’

- Views the patient’s own blood as a valuable and unique natural resource that should be conserved and managed appropriately
- An evidence-based, multidisciplinary team approach to **optimising the care of patients** who might need transfusion
- Focuses on measures for blood avoidance as well as **correct use of blood components when they are needed**
- Improves patient care – optimises use of donor blood and reduces transfusion-associated risks
- International initiative

Under or delayed transfused can result in major morbidity and mortality



Blood and Transplant

- Woman in mid-30's – ventouse-assisted vaginal delivery for fetal distress at term
 - Complicated by massive haemorrhage from cervical lacerations
 - Major haemorrhage protocol activated – 6 units of blood delivered and started within 5 minutes
 - Transferred from delivery suite to theatre – bleeding controlled within 30 minutes
 - Blood loss unclear – losses recorded in both delivery suite and theatre
 - 2 hours later – she suffered cardiac arrest – received 12 units red cells and 3 units FFP
 - She could not be resuscitated
- (Possible previous unrecognised coagulation factor XI deficiency, but no previous medical history to suggest this).



PBM – Key messages

- **Patient** - at the heart of decision making
- **Blood** – conserve patient's own blood, avoid transfusion where appropriate
- **Management** – organise and co-ordinate